What do systematic reviews say?

Oral vs intramuscular vitamin B12

• Oral vitamin B₁₂ versus intramuscular vitamin B₁₂ for vitamin B₁₂ deficiency 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Oral vs intravenous fluoropyrimidines

Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.93 [0.87, 1]
  7 studies · 8903 participants
  Moderate

Oral vs intravenous fluoropyrimidines

Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.17 [0.15, 0.18]
  29 studies · 11794 participants
  Low

Oral vs intravenous fluoropyrimidines

Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.92 [0.84, 1]
  7 studies · 8902 participants
  High

Oral vs intravenous fluoropyrimidines

It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 1.12 [0.99, 1.25]
  9 studies · 9551 participants
  Very low

Oral vs intravenous fluoropyrimidines

Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 4.59 [2.97, 7.1]
  5 studies · 5731 participants
  Low

Oral vs intravenous fluoropyrimidines

Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 0.14 [0.11, 0.16]
  7 studies · 8087 participants
  Moderate

Oral vs intravenous fluoropyrimidines

Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.06 [1.02, 1.11]
  23 studies · 9927 participants
  Moderate

Oral vs intravenous fluoropyrimidines

Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 1.02 [0.99, 1.05]
  29 studies · 12079 participants
  High

Oral vs intravenous fluoropyrimidines

Oral may leads to higher grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (low certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 1.66 [1.5, 1.84]
  30 studies · 11997 participants
  Low

Oral vs intravenous fluoropyrimidines

Oral probably leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (moderate certainty).

• Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
  OR 3.92 [2.84, 5.43]
  18 studies · 6481 participants
  Moderate

Oral vs IV antibiotics

Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).

• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients 2013 · Cochrane Headline outcomes only
  RR 0.95 [0.54, 1.68]
  9 studies · 1392 participants
  Moderate

Oral vs IV antibiotics

Oral showed no clear difference in treatment failure compared with intravenous antibiotic therapy (moderate certainty).

• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients 2013 · Cochrane Headline outcomes only
  RR 0.96 [0.86, 1.06]
  22 studies · 3142 participants
  Moderate

Oral vs IV antibiotics

Oral showed no clear difference in treatment failure ‐ per protocol analysis compared with intravenous antibiotic therapy (moderate certainty).

• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients 2013 · Cochrane Headline outcomes only
  RR 0.98 [0.86, 1.11]
  22 studies · 2912 participants
  Moderate

Oral vs IV antibiotics

Oral showed no clear difference in adverse events requiring discontinuation of antibiotics compared with intravenous antibiotic therapy (low certainty).

• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients 2013 · Cochrane Headline outcomes only
  RR 1.45 [0.61, 3.46]
  15 studies · 1823 participants
  Low

Oral vs IV antibiotics

Oral showed no clear difference in treatment failure not dt modification in update compared with intravenous antibiotic therapy (moderate certainty).

• Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients 2013 · Cochrane Headline outcomes only
  RR 0.95 [0.85, 1.06]
  21 studies · 3041 participants
  Moderate

Oral DHEA vs control subgrouped by differing routes of administration

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  Very low
• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 107 participants
  Very low

Oral DHEA vs control subgrouped by differing routes of administration

It is very uncertain whether oral DHEA changes side effects: acne ‐ oral administration compared with control subgrouped by differing routes of administration (very low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 2.16 [0.47, 9.96]
  3 studies · 136 participants
  Very low

Oral care interventions (nurse-assisted toothbrushing, oral and pharyngeal cavity rinse, decontamination with antibiotics or antiseptics) vs placebo

The review found no eligible studies for this question.

• Interventions for improving oral health in people after stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral care interventions (nurse-assisted toothbrushing, oral and pharyngeal cavity rinse, decontamination with antibiotics or antiseptics) vs placebo

The review found no eligible studies for this question.

• Interventions for improving oral health in people after stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found